Display options
Cite
Mathieu C, Ferrer L, Carlier T, et al. Assessment of Lymph Nodes and Prostate Status Using Early Dynamic Curves with (18)F-Choline PET/CT in Prostate Cancer. Front Med (Lausanne). 2015;2:67doi: 10.3389/fmed.2015.00067.
Mathieu, C., Ferrer, L., Carlier, T., Colombié, M., Rusu, D., Kraeber-Bodéré, F., Campion, L., & Rousseau, C. (2015). Assessment of Lymph Nodes and Prostate Status Using Early Dynamic Curves with (18)F-Choline PET/CT in Prostate Cancer. Frontiers in medicine, 267. https://doi.org/10.3389/fmed.2015.00067
Mathieu, Cédric, et al. "Assessment of Lymph Nodes and Prostate Status Using Early Dynamic Curves with (18)F-Choline PET/CT in Prostate Cancer." Frontiers in medicine vol. 2 (2015): 67. doi: https://doi.org/10.3389/fmed.2015.00067
Mathieu C, Ferrer L, Carlier T, Colombié M, Rusu D, Kraeber-Bodéré F, Campion L, Rousseau C. Assessment of Lymph Nodes and Prostate Status Using Early Dynamic Curves with (18)F-Choline PET/CT in Prostate Cancer. Front Med (Lausanne). 2015 Sep 09;2:67. doi: 10.3389/fmed.2015.00067. eCollection 2015. PMID: 26442269; PMCID: PMC4563255.
Copy Download .nbib Format: NLM
Share it on

Front Med (Lausanne). 2015 Sep 09;2:67. doi: 10.3389/fmed.2015.00067. eCollection 2015.

Assessment of Lymph Nodes and Prostate Status Using Early Dynamic Curves with (18)F-Choline PET/CT in Prostate Cancer.

Frontiers in medicine

Cédric Mathieu, Ludovic Ferrer, Thomas Carlier, Mathilde Colombié, Daniela Rusu, Françoise Kraeber-Bodéré, Loic Campion, Caroline Rousseau

Affiliations

  1. Department of Nuclear Medicine, ICO Cancer Center , Saint Herblain , France ; Department of Nuclear Medicine, University Hospital , Nantes , France.
  2. Centre Régional de Recherche en Cancérologie Nantes/Angers, U892, CNRS UMR 6299, INSERM , Nantes , France ; Department of Medical Physics, ICO Cancer Center , Saint Herblain , France.
  3. Department of Nuclear Medicine, University Hospital , Nantes , France ; Centre Régional de Recherche en Cancérologie Nantes/Angers, U892, CNRS UMR 6299, INSERM , Nantes , France.
  4. Department of Nuclear Medicine, ICO Cancer Center , Saint Herblain , France.
  5. Department of Nuclear Medicine, ICO Cancer Center , Saint Herblain , France ; Department of Nuclear Medicine, University Hospital , Nantes , France ; Centre Régional de Recherche en Cancérologie Nantes/Angers, U892, CNRS UMR 6299, INSERM , Nantes , France.
  6. Department of Statistics, ICO Cancer Center , Saint Herblain , France.
  7. Department of Nuclear Medicine, ICO Cancer Center , Saint Herblain , France ; Centre Régional de Recherche en Cancérologie Nantes/Angers, U892, CNRS UMR 6299, INSERM , Nantes , France.

PMID: 26442269 PMCID: PMC4563255 DOI: 10.3389/fmed.2015.00067

Abstract

INTRODUCTION: Dynamic image acquisition with (18)F-Choline [fluorocholine (FCH)] PET/CT in prostate cancer is mostly used to overcome the bladder repletion, which could obstruct the loco-regional analysis. The aim of our study was to analyze early dynamic FCH acquisitions to define pelvic lymph node or prostate pathological status.

MATERIAL AND METHODS: Retrospective analysis was performed on 39 patients for initial staging (n = 18), or after initial treatment (n = 21). Patients underwent 10-min dynamic acquisitions centered on the pelvis, after injection of 3-4 MBq/kg of FCH. Whole-body images were acquired about 1 h after injection using a PET/CT GE Discovery LS (GE-LS) or Siemens Biograph mCT (mCT). Maximum and mean SUV according to time were measured on nodal and prostatic lesions. SUVmean was corrected for partial volume effect (PVEC) with suitable recovery coefficients. The status of each lesion was based on histological results or patient follow-up (>6 months). A Mann-Whitney test and ANOVA were used to compare mean and receiver operating characteristic (ROC) curve analysis.

RESULTS: The median PSA was 8.46 ng/mL and the median Gleason score was 3 + 4. Ninety-two lesions (43 lymph nodes and 49 prostate lesions) were analyzed, including 63 malignant lesions. In early dynamic acquisitions, the maximum and mean SUV were significantly higher, respectively, on mCT and GE-LS, in malignant versus benign lesions (p < 0.001, p < 0.001). Mean SUV without PVEC, allowed better discrimination of benign from malignant lesions, in comparison with maximum and mean SUV (with PVEC), for both early and late acquisitions. For patients acquired on mCT, area under the ROC curve showed a trend to better sensitivity and specificity for early acquisitions, compared with late acquisitions (SUVmax AUC 0.92 versus 0.85, respectively).

CONCLUSION: Assessment of lymph nodes and prostate pathological status with early dynamic imaging using PET/CT FCH allowed prostate cancer detection in situations where proof of malignancy is difficult to obtain.

Keywords: 18F-choline; dynamic curves; early acquisition; pathological status; prostate cancer

References

  1. J Urol. 1999 Oct;162(4):1322-8 - PubMed
  2. J Nucl Med. 2001 Dec;42(12):1805-14 - PubMed
  3. Eur Urol. 2005 Oct;48(4):546-51 - PubMed
  4. J Nucl Med. 2005 Aug;46(8):1342-8 - PubMed
  5. J Nucl Med. 2006 Feb;47(2):262-9 - PubMed
  6. Clin Radiol. 2008 Apr;63(4):387-95 - PubMed
  7. Nuklearmedizin. 2009;48(1):1-9; quiz N2-3 - PubMed
  8. Radiology. 2010 Mar;254(3):925-33 - PubMed
  9. Eur Urol. 2011 Jan;59(1):51-60 - PubMed
  10. J Nucl Med. 2011 Jan;52(1):81-9 - PubMed
  11. Urol Oncol. 2013 May;31(4):427-35 - PubMed
  12. J Nucl Med. 2012 May;53(5):701-8 - PubMed
  13. Eur J Nucl Med Mol Imaging. 2012 Nov;39(11):1670-2 - PubMed
  14. PLoS One. 2012;7(10):e48430 - PubMed
  15. Clin Nucl Med. 2013 May;38(5):305-14 - PubMed
  16. Biomed Res Int. 2013;2013:780458 - PubMed
  17. Eur Urol. 2014 Jan;65(1):124-37 - PubMed
  18. AJR Am J Roentgenol. 2013 Dec;201(6):1229-38 - PubMed
  19. Eur Urol. 2014 Feb;65(2):467-79 - PubMed
  20. Prog Urol. 2013 Nov;23 Suppl 2:S69-101 - PubMed
  21. J Nucl Med. 2014 May;55(5):753-8 - PubMed
  22. AJR Am J Roentgenol. 2014 May;202(5):W459-65 - PubMed
  23. J Urol. 2014 Sep;192(3):648-58 - PubMed
  24. Nucl Med Commun. 2015 Jan;36(1):8-15 - PubMed
  25. PET Clin. 2009 Apr;4(2):173-84 - PubMed

Publication Types